The glaucoma journey
Built to lead
Empowering surgeons to stay ahead in the race against glaucoma
Whether combined with cataract surgery or for pseudophakic patients, OMNI delivers a comprehensive solution at every stage.
Stay on track
precision in motion
Join the Race

You’re in control at every turn

A winning history of proven performance with consistent, real-world results.3,4
Get in the lead
Caroline Watson, MD
Huntsville, AL
Meet the Drivers
Experience OMNI Edge
Ready to take the wheel?
Experience OMNI Edge
Are you ready to take the wheel?
Learn More
what to expect
Three days. Full throttle. Maximum power.
what to expect
Three days. Full throttle. Maximum power.
See the full schedule
drivers wanted
Join your peers
Contact Us
Technology

OMNI Edge Surgical System

Evolving from the proven OMNI® platform, OMNI® Edge is an implant-free, minimally invasive MIGS device designed for canaloplasty followed by trabeculotomy to lower intraocular pressure in POAG patients. With an expanded 21-microliter viscoelastic reservoir—double the capacity of OMNI —OMNI® Edge supplies more OVD per cycle providing surgeon confidence in canal dilation.
Learn More
Procedure Guide
Device Sales Aid
Important Product Information

Meet Team OMNI: Champions of Interventional Glaucoma

Drivers Wanted

Gain access to data benchmarking, patient materials, training, and ongoing support to stay at the front of care for your primary open-angle glaucoma patients.

Join Team OMNI
Leaders in the field, our certified interventional glaucoma champions, have taken the wheel with engineered precision and comprehensive performance to drive proven outcomes.
Jason
Bacharach
MD
Matthew
Brink
MD
Christine
Funke
MD
Douglas
McGraw
DO
Deb
Ristvedt
DO
Chris
Spearman
MD
Arkadiy
Yadgarov
MD
Caroline
Watson
MD

1. The OMNI® Edge Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. Please visit omnisurgical.com/instructionsforuse for the full instructions for use, warnings, precautions, and adverse event information.
2. Hirsch L, et al. Canaloplasty and trabeculotomy ab interno with the OMNI system combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO study. J Cataract Refract Surg 2021; 47:907–915.
3. Williamson B, et al. Canaloplasty and Trabeculotomy with OMNI System in Patients with Open-Angle Glaucoma: Two-Year Results from the ROMEO study. Clinical Ophthalmology 2023: 17 1-10.
4. Radcliffe, Nathan M, et al. Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System in Eyes with Primary Open-Angle Glaucoma: A 36-Month Analysis from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) American Journal of Ophthalmology, Volume 271, 436 – 444.
5. Estimate based on units of OMNI (and predicates) shipped as of Dec 31, 2024.
6. Greenwood M, et al. 36-Month Outcomes from the Prospective GEMINI Study: Canaloplasty and Trabeculotomy Combined with Cataract Surgery for Patients with Primary Open-Angle Glaucoma. Clinical Ophthalmology 2023:17 3817-3824.
7. Yadgarov A, et al. Real-World Outcomes of Canaloplasty and Trabeculotomy Combined with Cataract Surgery in Eyes with All Stages of Open-Angle Glaucoma. Clinical Ophthalmology 2023:17 2609-2617.

OM-3641-US.v2

Join in the race against glaucoma.

Get Started